women’s health illness and disabilities-psoriasis; natural lifestyle advisor) 2010 (accessed 5 april 2016).
Daniel J, Roach P, Hartmann J. 978-3-12 (accessed 5 april 2016).
Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN, Mule PM. Psoriasis: A comprehensive review. int j pharm life sci 2011; 2(6)
Shan Y. Treatment and management of psoriasis. Prim Health Care 2016; 26(3): 32-41.
Thaker SJ, Mehta DS, Shah HA, Dave JN, Mundhava SG. A comparative randomized open label study to evaluate. Indian Dermatol Online J 2010; 1(1): 8-9.
Murphy EC, Schaffter SW, Friedman AJ. Nanotechnology for psoriasis therapy. Curr Dermatol Rep 2019; 8(1): 14-25.
Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis
Rahman M, Akhter S, Ahmad J. nano medicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. epert opinion on drug delivery 2015; 312(4): 635-52.
Patel R, Singh SK, Singh S, Sheth NR, Gendle R. Development and characterization of curcumin loaded transfersome for transdermal delivery. journal of pharmaceutical sciences and research 2009; 11(4): 71.
Srikanth K, Rama Mohan Gupta V, Manvi SR. Particulate carrier systems: a review. int res j pharm 2012. 3(110: 22-6.
Halnor VV, Pande VV, Borawake DD, Nagare HS. Nanoemulsion: A novel platform for drug delivery system. J Mat Sci Nanotechol 2018; 6(1): 104.
Sieber S, Grossen P, Uhi P, et al. Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo. Nanomedicine 2019; 17: 82-93.
Korade S, Deshmukh MT, Shete RV. Formulation and evaluation of ethosomal gel containing clobetasol J Eur Pharm Med Res 2016; 3: 664-72.
Garg A. herbal nanotherapeutics: a noval approach for herbal drug delivery system. j med pharm allied sci 2016; 201(10): 1.
Horvath F. therapeutical compositions against psoriasis. us patent 5165932 1992.
Shrivastava S, Sindhu KR, Kumar S, Kumar S, Kumar P. Antipsoriatic and phytochemical evaluation of Thespesiapopulnea bark extracts. Int J Pharma Sci 2009; 1: 176-85.
Cellzome Ltd. heterocyclyl pyrimidine analogs as tyk2 inhibitors. us 9296725,
Roche AG. thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors. wo patent 2015091584, 2015.
Takeda Pharmaceutical Company Ltd. heterocyclic com-pound. wo2015016206.,, (*excellent tyk2 inhibitory effect)
Lakshimi N. tyk2 inhibitors and uses thereof. wo patent 2015131080 2015.
Research programme: autoimmune disorder therapies 2010 [accessed 5 april 2016].
Arrien pharmaceuticals – adis insight [accessed 5 april 2016].
concert pharmaceuticals inc. deuterated derivatives of ruxo-litinib wo patent 20131887831, 2013.
Schafer PH, Gandhi A, Capone L. inventors; celgene c. methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases. us patent us patent 9272035, 2016.
Kakar R, Rao R, Goswami A, Nanda S, Saroha K. Proniosomes: An emerging vesicular system in drug delivery and cosmetics. Der Pharmacia Lettre 2010; 2(4): 227-39.
Wagner A, Vorauer-Uhl K. liposome technology for industrial purposes. j drug deliv 2011 2011.